

Development of a lead compound for preventing Parkinson's disease using small compounds with inhibitory mechanism of initial alpha-synuclein aggregation

Hanyang University



NEUROSCIENCE	Hit
Product Type	Chemical Product
Indication	Parkinson Disease [MeSH term]
Target	Confidential
MoA(Mechanism of Action)	Inhibition of initial alpha-synuclein aggregation
Competitiveness	<ul style="list-style-type: none"> • No preventive drug is available for Parkinson's disease up to now • No drug is available for Parkinson's disease with inhibitory mechanism of initial alpha-synuclein aggregation
Development Stage	Hit
Route of Administration	Oral Administration